Add a new comment

Momentum stocks experienced a correction since Pfizer announced their Covid-19 vaccine results early November. Performance has nonetheless stabilized over the course of March, as the rebound in Value stocks has been persistent and started to be shown in the Momentum risk factor.

12 April, by Lyxor Research

Access restricted to registered visitors

Prior to participating, you must register register.

Connection | Register (free)